Urolithin A: a multi-target therapeutic candidate derived from the gut microbiota for obesity and metabolic dysfunction - PubMed
6 hours ago
- #Urolithin A
- #Gut Microbiota
- #Obesity
- Urolithin A (UroA) is a gut microbial metabolite from dietary ellagitannins, showing promise for treating obesity and metabolic disorders.
- Its production varies among individuals due to gut microbiota differences, affecting responsiveness to dietary interventions.
- UroA works through multiple pathways: activating thermogenesis in adipose tissue, regulating lipid metabolism, reducing inflammation via macrophage polarization, and modulating gut microbiota and intestinal barrier.
- These mechanisms collectively improve insulin sensitivity, glucose homeostasis, and reduce lipid accumulation.
- While preclinical evidence is strong, further large-scale clinical trials are needed to confirm efficacy in humans.
- UroA is a key molecule in the diet-microbiota-host axis, offering potential for personalized nutrition strategies.